TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34668923

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 33733955

Group type: EXPERIMENTAL
Intervention: Child-report ratings on psychosocial measures
Number of subjects: 200

Group type: COMPARATOR
Intervention: Parent-report ratings on psychosocial measures
Number of subjects: 200
Study: 33023067

Group type: EXPERIMENTAL
Intervention: 400 mg/d algal DHA
Number of subjects: 957

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 957
Study: 35807852

Group type: EXPERIMENTAL
Intervention: Intensive mobile nutritional education for a year
Number of subjects: 203

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 203
Study: 34842540

Group type: EXPERIMENTAL
Intervention: Emotional voice
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Emotional voice (for women)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Neutral voice (for men)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Neutral face (for women)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: No face (voice-only black screen for men)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Emotional voice (for men)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Neutral face and emotional face
Number of subjects: 198
Study: 34369679

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) applied to bilateral Hegu (LI4) and Quchi (LI11), once an hour, for 30 min each time, till the end of childbirth
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (TEAS electrodes attached to the same acupoints without electric stimulation)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 35128402

Group type: EXPERIMENTAL
Intervention: Nichi Glucan 0.5 g two times per day along with conventional treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional treatment comprising remedial behavioural therapies and L‐carnosine 500 mg per day
Number of subjects: 18
Study: 32033793

Group type: EXPERIMENTAL
Intervention: Heart rate characteristics monitoring displayed
Number of subjects: 884

Group type: COMPARATOR
Intervention: Heart rate characteristics monitoring not displayed (Control)
Number of subjects: 884
Study: 35857132

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (Lactobacillus acidophilus UBLA‐34, L. rhamnosus UBLR‐58, L. reuteri UBLRu‐87 (2 billion CFU each), L. plantarum UBLP‐40, L. casei UBLC‐42, L. fermentum UBLF‐31, Bifidobacterium bifidum UBBB‐55 (1 billion CFU each) and fructo‐oligosaccharides (100 mg)) along with dietary and lifestyle modifications
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic along with dietary and lifestyle modifications
Number of subjects: 104
Study: 35725626

Group type: EXPERIMENTAL
Intervention: Spotlight Consultations pre-clinic assessment
Number of subjects: 200
Study: 34164808

Group type: EXPERIMENTAL
Intervention: Overall survival rates at 1 year, 3 years, and 5 years for patients with CRC across all registries combined.
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Relative survival at 5 years for patients with CRC.
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Factors associated with poorer survival.
Number of subjects: 1707
Study: 32490570

Group type: EXPERIMENTAL
Intervention: Tumor debulking followed by chemotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard treatment with chemotherapy
Number of subjects: 88
Study: 35292397

Group type: EXPERIMENTAL
Intervention: Dual-release bilayer tablets containing sarpogrelate HCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo layer
Number of subjects: 0
Study: 36045227

Group type: EXPERIMENTAL
Intervention: 22G crown-cut needle
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional 22G needle
Number of subjects: 30
Study: 34951464

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (oral; 0.43 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 32382551

Group type: EXPERIMENTAL
Intervention: anti-VEGF treatment (ProReNata approach)
Number of subjects: 51
Study: 35583486

Group type: EXPERIMENTAL
Intervention: Ratanasampil (RNSP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Flunarizine (FLZ)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 33455753

Group type: EXPERIMENTAL
Intervention: Automated device (AMD alerts provided to farm personnel)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control (AMD alerts not provided to farm personnel)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Automated device
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Clinical disease without AMD alerts
Number of subjects: 610

Group type: COMPARATOR
Intervention: Clinical disease with AMD alerts
Number of subjects: 610
Study: 32272886

Group type: EXPERIMENTAL
Intervention: Co-management by PCPs and nephrologists
Number of subjects: 242

Group type: COMPARATOR
Intervention: Management by PCPs with written instructions and consultations by nephrologists on demand (standard care)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 242
Study: 36404400

Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg daily, titrated to 200 mg daily, n=39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 80
Study: 33153929

Group type: COMPARATOR
Intervention: Conventional follow-up (arm A) with carcinoembryonic antigen, liver echography, and alternated lung radiography and CT scans
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: PET/CT follow-up (arm B) every 6 months
Number of subjects: 365
Study: 32643530

Group type: EXPERIMENTAL
Intervention: Softshell ankle brace (AE)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Semi-rigid ankle brace (T1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No braces
Number of subjects: 39
Study: 35620165

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (once per week intravenous)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Epoetin alfa (twice or three times per week intravenous)
Number of subjects: 95
Study: 32130261

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 136
Study: 34940699

Group type: EXPERIMENTAL
Intervention: Whole biomass of Phaeodactylum tricornutum (PT) at 5.3 g/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fish oil (FO) containing equal amounts of EPA and DHA (300 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sea fish at 185 g/week resulting in similar EPA and DHA intake
Number of subjects: 22
Study: 32070847

Group type: EXPERIMENTAL
Intervention: Chewing gum intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 59
Study: 35795994

Group type: EXPERIMENTAL
Intervention: Prehabilitation during neoadjuvant therapy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Prehabilitation with ≥75% adherence to exercise
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Prehabilitation with increasing volumes of exercise
Number of subjects: 79

Group type: COMPARATOR
Intervention: Loss of VAT during neoadjuvant therapy
Number of subjects: 79
Study: 34371975

Group type: EXPERIMENTAL
Intervention: Enhanced diet, PA, and sleep intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Pooled intervention group
Number of subjects: 116
Study: 33973085

Group type: EXPERIMENTAL
Intervention: Transseptal sutures
Number of subjects: 180

Group type: COMPARATOR
Intervention: Merocel packing
Number of subjects: 180

Group type: COMPARATOR
Intervention: Silicone packing
Number of subjects: 180
Study: 34181148

Group type: EXPERIMENTAL
Intervention: Oxycodone-paracetamol (OPT group)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Celecoxib (CEL group)
Number of subjects: 232
Study: 33450060

Group type: EXPERIMENTAL
Intervention: 30‐min computer intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual curriculum waitlist (Control)
Number of subjects: 80
Study: 32154123

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (oral, flexibly dosed, 1.5‐12 mg/day)
Number of subjects: 324
Study: 35260947

Group type: EXPERIMENTAL
Intervention: Psychosocial depression and adherence intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 23
Study: 33248115

Group type: EXPERIMENTAL
Intervention: High-volume feeding (180-200 mL/kg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual volume feeding (140-160 mL/kg/day)
Number of subjects: 86
Study: 32993832

Group type: EXPERIMENTAL
Intervention: Implementation of a package of noncommunicable disease interventions including cardiovascular risk scoring, hypertension management, and statin treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focused clinical training and support for primary health care providers.
Number of subjects: 0
Study: 36225985

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Guchi recipe for 3 courses while basic periodontal treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic periodontal treatment without taking any drugs
Number of subjects: 60
Study: 35065710

Group type: EXPERIMENTAL
Intervention: Daridorexant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32761109

Group type: EXPERIMENTAL
Intervention: Feedback-based oculomotor training (dichoptic feedback paradigm)
Number of subjects: 32
Study: 35074136

Group type: EXPERIMENTAL
Intervention: Ad26.COV2-S (Janssen)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: BNT162b2 (Pfizer-BioNTech)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (AstraZeneca)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: CoronaVac (homologous boost)
Number of subjects: 1240
Study: 34028130

Group type: EXPERIMENTAL
Intervention: Cold therapy before amniocentesis (group 1)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Cold therapy after amniocentesis (group 2)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Cold therapy before and after amniocentesis (group 3)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 480
Study: 34990968

Group type: EXPERIMENTAL
Intervention: Adjuvant clonidine (0.2 mg/d to a maximum of 0.6 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 33369985

Group type: EXPERIMENTAL
Intervention: Volar Locking Plate (VLP)
Number of subjects: 156

Group type: COMPARATOR
Intervention: External Fixation (EF)
Number of subjects: 156
Study: 32878521

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus axitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 34328293

Group type: EXPERIMENTAL
Intervention: Klinefelter Syndrome (KS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Y chromosome microdeletions (Myc)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CFTR gene mutations (CFTR)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (obstructive azoospermia)
Number of subjects: 26
Study: 34181875

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33561199

Group type: EXPERIMENTAL
Intervention: Surface area‐to‐volume ratio of culture medium, oil density, and oil thickness above the medium
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Multi-factor experiment with a combination of surface area‐to‐volume ratio, oil density, and oil thickness
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Repeatability of identical treatments
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Final mathematical model
Number of subjects: 107
Study: 35435813

Group type: EXPERIMENTAL
Intervention: OPT-IN tobacco treatment
Number of subjects: 1000

Group type: COMPARATOR
Intervention: OPT-OUT tobacco treatment
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Participants who consented (n=741)
Number of subjects: 1000
Study: 34143760

Group type: EXPERIMENTAL
Intervention: Patients with complicated surgical site infection (SSI)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Patients without surgical site infection (SSI)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Patients with surgical site infection (SSI)
Number of subjects: 535
Study: 32171749

Group type: EXPERIMENTAL
Intervention: Step-by-step video demonstration
Number of subjects: 43

Group type: COMPARATOR
Intervention: Continuous video demonstration
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Step-by-step video demonstration (1 to 2 hours preparation)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Continuous video demonstration (1 to 2 hours preparation)
Number of subjects: 43
Study: 35096134

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block combined with rectus abdominis sheath block and general anesthesia
Number of subjects: 160

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 160
Study: 35109502

Group type: EXPERIMENTAL
Intervention: Multicomponent Training (MT) intervention (2 sessions per week, 50 minutes per session for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (monthly recreational session during the same period)
Number of subjects: 40
Study: 32536019

Group type: EXPERIMENTAL
Intervention: 200 mg of vaginal micronised progesterone daily (vaginal group)
Number of subjects: 266

Group type: COMPARATOR
Intervention: 250 mg 17α-hydroxyprogesterone caproate weekly (IM group)
Number of subjects: 266
Study: 34969609

Group type: EXPERIMENTAL
Intervention: Qualified practitioner Johrei treatment
Number of subjects: 225

Group type: COMPARATOR
Intervention: Non-qualified operator treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Qualified practitioner Johrei treatment for hypothermia tendency subjects
Number of subjects: 225

Group type: COMPARATOR
Intervention: Non-qualified operator treatment for hypothermia tendency subjects
Number of subjects: 225
Study: 34510189

Group type: EXPERIMENTAL
Intervention: 67 g/d of soy nuts providing ~25.5 g protein and 174 mg isoflavones
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 67 g/d of soy nuts
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control period (no nuts)
Number of subjects: 23
Study: 34798600

Group type: EXPERIMENTAL
Intervention: Anterior entry site for shunt placement
Number of subjects: 467

Group type: COMPARATOR
Intervention: Posterior entry site for shunt placement
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Both anterior and posterior entry sites
Number of subjects: 467
Study: 35709019

Group type: EXPERIMENTAL
Intervention: Restrictive intravenous fluid therapy
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Standard intravenous fluid therapy
Number of subjects: 1554
Study: 32095401

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 60
Study: 33196584

Group type: EXPERIMENTAL
Intervention: Self-administered daily low-intensity pulsed ultrasound
Number of subjects: 428

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: BMI > 30 kg/m2
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Receipt of disability benefits or involvement in litigation
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Surgeon's advice to partially or fully bear weight postoperatively
Number of subjects: 428
Study: 35993875

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 33439978

Group type: EXPERIMENTAL
Intervention: 60 mg Fe as ferrous fumarate with 0 mg folic acid
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: 60 mg Fe as ferrous fumarate with 0.4 mg folic acid
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: 60 mg Fe as ferrous fumarate with 2.8 mg folic acid
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 331
Study: 32885389

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non‐steroidal anti‐inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐17 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐23 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JAK pathway alteration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDE‐4 inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐6 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T‐cell co‐stimulation blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination biologic therapy
Number of subjects: 0
Study: 36451130

Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 27

Group type: COMPARATOR
Intervention: Water
Number of subjects: 27
Study: 35058800

Group type: EXPERIMENTAL
Intervention: Mild Intermittent Hypoxia (MIH) exposure (FiO2 15%, 3x2h/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normoxia exposure (FiO2 21%)
Number of subjects: 0
Study: 35091727

Group type: EXPERIMENTAL
Intervention: Microneedle device delivered topical steroids
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical Daivobet gel (control)
Number of subjects: 25
Study: 34450257

Group type: EXPERIMENTAL
Intervention: Integrated yoga and mindfulness-based programme (16 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional primary school lessons
Number of subjects: 40
Study: 35452365

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study: 34029296

Group type: EXPERIMENTAL
Intervention: Personal exercise supervision (SUP; n=21)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Non-personal exercise supervision (NPS; n=19)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (CON; n=16)
Number of subjects: 56
Study: 32805133

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB) plus medical therapy (MT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy (MT) alone
Number of subjects: 100
Study: 35623596

Group type: EXPERIMENTAL
Intervention: High sun exposure (≥ 15 h/week)
Number of subjects: 5039

Group type: COMPARATOR
Intervention: Low sun exposure (< 15 h/week)
Number of subjects: 5039
Study: 33750376

Group type: EXPERIMENTAL
Intervention: Paula Exercise Method (PEM)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 182
Study: 32544925

Group type: EXPERIMENTAL
Intervention: Kappa-opioid receptor (KOR) antagonist for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kappa-opioid receptor (KOR) antagonist
Number of subjects: 0
Study: 34348227

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) exercise (16 weeks, 3 × 20 min/week, starting with 5 × 1 min bouts at 6 Hz/2 mm, progressing to 10 × 1 min at up to 26 Hz/4 mm)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Simulated exercise (SIM) (16 weeks, 3 × 20 min/week, mimicking exercise stance and duration)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (regular care only)
Number of subjects: 117
Study: 33792952

Group type: EXPERIMENTAL
Intervention: Open-resource conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed-resource conditions
Number of subjects: 0
Study: 32192678

Group type: EXPERIMENTAL
Intervention: Chronic low level tragus stimulation (LLTS) at 20 Hz, 1 mA below discomfort threshold for 1 hour daily over 6 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Chronic low level tragus stimulation (LLTS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham control stimulation
Number of subjects: 53
Study: 33247624

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-pro-BNP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Galectin-3
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 and change in NT-pro-BNP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Biomarkers (NT-pro-BNP and galectin-3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NT-pro-BNP and galectin-3
Number of subjects: 80
Study: 32448804

Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with apatinib (continuous dosing)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with apatinib (intermittent dosing)
Number of subjects: 40
Study: 35468658

Group type: EXPERIMENTAL
Intervention: Variable selection procedure in semiparametric regression models for longitudinal data with informative observation times
Number of subjects: 0
Study: 33358692

Group type: EXPERIMENTAL
Intervention: Chlormethine/mechlorethamine gel
Number of subjects: 0
Study: 36300769

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 277
Study: 34075780

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 404
Study: 34822214

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac (1 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous ketorolac (0.5 mg/kg)
Number of subjects: 59
Study: 35266779

Group type: EXPERIMENTAL
Intervention: Buspirone (45 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 35774632

Group type: EXPERIMENTAL
Intervention: Global osteopathic protocol (myofascial, visceral, and articular techniques)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Manipulation technique (high-velocity, low-amplitude/thrust) of the sacroiliac joint and T10-L2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Training of the pelvic floor muscles
Number of subjects: 51

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 51
Study: 35226276

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg of elemental zinc daily for 24 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69